Cancer Drugs Dominate Top 10 Best-Selling Drugs in 2018
Adalimumab (Humira, AbbVie) remains the top selling drug in the United States for 2 years running, racking in $19.9 billion in sales in 2018 and $18.4 billion in 2017, according to a biobusiness brief in Nature Reviews Drug Discovery.
Two factors that might keep Humira on top a bit longer: AbbVie recently increased by 6.2%...
FDA Approves Pfizer's Biosimilar to Roche's Herceptin
(Reuters) - The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin (trastuzumab).
The approval comes nearly a year after the agency declined to approve the drug, Trazimera, and sought additional technical information.
Since then, the FDA has approved a biosimilar to Herceptin from...
Trump Budget Seeks 12% HHS Cut, Medicaid Work Rules, FDA Boost
WASHINGTON — The Trump administration on Monday unveiled in its proposed budget a bid to make a sizeable cut in total funding for federal health programs and also pressed for Medicaid block grants and expansion of its work rules.
The White House released an overview of its request to Congress for fiscal 2020, which begins...
